13136-53-3

Basic information

• Product Name: (S)-(+)-2-(4-toluenesulfonyloxy)-phenylacetic acid methyl ester
• Synonyms: (S)-(+)-2-(4-toluenesulfonyloxy)-phenylacetic acid methyl ester
• CAS NO: 13136-53-3
• Molecular Weight: 320.366
• Mol File: 13136-53-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (S)-(+)-2-(4-toluenesulfonyloxy)-phenylacetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(+)-2-(4-toluenesulfonyloxy)-phenylacetic acid methyl ester(13136-53-3)
• EPA Substance Registry System: (S)-(+)-2-(4-toluenesulfonyloxy)-phenylacetic acid methyl ester(13136-53-3)

Safety Data

• Hazardous Substances Data: 13136-53-3(Hazardous Substances Data)

Upstream product

• 21210-43-5 (S)-Methyl mandelate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 2135284-21-6 (R)-1-N-tert-butoxycarbonyl-2-phenylpiperazin-3-one 
• 1240585-54-9 (R)-3-phenyl-2-piperazinone 
• 1191446-39-5 (2R,αR)-α-(2-carbamoylpiperidinyl)-α-phenylacetic acid methyl ester 
• 1191446-36-2 (4S,9aS)-4-phenylperhydropyrido[1,2-a]pyrazine-1,3-dione 
• 1191446-34-0 (4R,9aS)-4-phenylperhydropyrido[1,2-a]pyrazine-1,3-dione 
• 1191446-35-1 (2S,αS)-α-(2-carbamoylpiperidinyl)-α-phenylacetic acid methyl ester 
• 1191446-33-9 (2S,αR)-α-(2-carbamoylpiperidinyl)-α-phenylacetic acid methyl ester 
• 958852-30-7 (2S,αS)-α-(2-carbamoylpyrrolidin-1-yl)-α-phenylacetic acid methyl ester 
• 958852-31-8 (2S,αR)-α-(2-carbamoylpyrrolidin-1-yl)-α-phenylacetic acid methyl ester 

Relevant articles and documents

A new method for the resolution of amines and its application to 3-amino-1,5-benzodiazepines

A new method for the resolution of racemic amines and its application to 3-amino-1,5-benzodiazepines is reported. The method is based upon the reaction of the amines with a chiral auxiliary, namely the tosyl derivative of (S)-(+)-methyl mandelate, followe

Application of piperazine structure containing compound to preparation of LSD1 (Lysine Specific Demethylase 1) inhibitor

The invention discloses application of a piperazine structure containing compound to the preparation of a histone lysine specific demethylase (LSD1) inhibitor. The structural general formula of the compound is as shown in the following descriptions (wherein, A is hydrogen, carbonyl or thiocarbonyl) or a configurational isomer and a pharmaceutical salt thereof, or is as shown in the following descriptions or a pharmaceutical salt thereof. The compound has an obvious inhibition effect on the LSD1, can be prepared into the LSD1 inhibitor, and is used for preventing and treating a disease related to the activity of the histone LSD1.